Beta Bionics (BBNX) Bank of America Global Healthcare Conference 2026 summary

Business performance and market trends

• Achieved a strong Q1 with revenue exceeding expectations by 2.5%, driven by increased adoption in the pharmacy channel, where patient out-of-pocket costs are significantly lower than DME reimbursement.

• Expansion of the field sales team is underway, with plans to add at least 20 new U.S. territories in 2026, front-loaded in the first half of the year.

• Q1 new patient starts were in line with expectations despite industry-wide softness, attributed to typical seasonality patterns.

• The insulin pump market remains healthy, with continued growth in both Type 1 and Type 2 diabetes segments.

• Confident in predictable new patient starts due to historical data and territory ramp rates.

Product differentiation and innovation

• Emphasizes a differentiated product with strong clinical outcomes and a robust algorithm, maintaining a competitive edge in the tubed pump market.

• Plans to launch a patch pump, Mint, by the end of 2027, aiming for a user experience equal to or better than the incumbent, with no recharging required.

• Ongoing innovation in algorithm development, including fully automated and bi-hormonal (insulin and glucagon) technologies.

• Manufacturing readiness is the primary gating factor for Mint’s launch, with parallel progress on regulatory and manufacturing fronts.

• Manufacturing expertise in disposable products and semi-automated environments supports confidence in scaling production.

Pharmacy channel strategy and pricing

• Pharmacy channel adoption offers lower out-of-pocket costs for patients and a recurring revenue model, preferred by payers for its risk transfer and ongoing payment structure.

• Insulin pumps are not commoditized; pricing is expected to remain rational and sustainable due to product differentiation and physician-patient matching.

• Tier 2 and Tier 3 pharmacy benefit positions are evaluated based on rebate and copay economics, with copay buy-downs ensuring patient costs remain low.

• Pricing disclosed in the pharmacy channel is net of all rebates, copay assistance, and discounts.

• Transitioning patients from DME to pharmacy channel is straightforward, with no blocking mechanisms in place.